Cargando…
Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation
BACKGROUND: Pulmonary autograft reinforcement to prevent dilatation and subsequent neo-aortic valve regurgitation has been reported; however, data on long-term function of the neo-aortic valve after this modified Ross procedure are lacking. Our objective here was to assess long-term outcomes of the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938391/ https://www.ncbi.nlm.nih.gov/pubmed/36820346 http://dx.doi.org/10.1016/j.xjtc.2022.11.016 |
_version_ | 1784890618822000640 |
---|---|
author | Guirgis, Lisa Hascoet, Sébastien Van Aerschot, Isabelle Radojevic, Jelena Ly, Mohamed Cohen, Sarah Belli, Emre |
author_facet | Guirgis, Lisa Hascoet, Sébastien Van Aerschot, Isabelle Radojevic, Jelena Ly, Mohamed Cohen, Sarah Belli, Emre |
author_sort | Guirgis, Lisa |
collection | PubMed |
description | BACKGROUND: Pulmonary autograft reinforcement to prevent dilatation and subsequent neo-aortic valve regurgitation has been reported; however, data on long-term function of the neo-aortic valve after this modified Ross procedure are lacking. Our objective here was to assess long-term outcomes of the modified Ross procedure with autograft reinforcement using the reimplantation technique. PATIENTS: The outcomes of 61 consecutive patients managed using the Dacron-conduit reinforced Ross procedure between 2009 and 2021 were reviewed. Most patients had a unicuspid or bicuspid aortic valve (n = 52; 85%), predominant aortic valve regurgitation (n = 42; 77%), and >30 mm dilatation of the ascending aorta (n = 33; 54%). A prior aortic valve procedure was noted in 47 patients (77%) patients, including 38 (62%) with surgical repair and 9 (15%) with balloon dilatation. The pulmonary autograft was reimplanted within a Dacron conduit with a median diameter of 25.6 mm (range, 20-30 mm) using the David valve-sparing aortic root replacement technique. RESULTS: All patients survived. The median age at surgery was 16.8 years (range, 6-38 years). Neo-aortic valve replacement was required in 3 patients (4.9%; 95% CI, 0.34%- 12.7%) because of infective endocarditis, left ventricular false aneurysm, and leaflet perforation, respectively; the repeat procedure was done early in 2 of these patients (2 of 61; 3%). Six patients required right ventricular outflow conduit replacement, 5 by surgery and 1 percutaneously. The median duration of follow-up was 90 months (range, 10-124 months). The 5- and 10-year rates of reintervention-free survival were 84.3% (95% CI, 74%-95%) and 81.6% (95% CI, 72%-93%), respectively, and 5-year survival without aortic reintervention was 94.5% (95% CI, 88%-100%), with little change at 10 years. No patients experienced deterioration of initial neo-aortic valve function (ie, regurgitation or stenosis). CONCLUSIONS: Autograft reinforcement using the reimplantation technique allowed expansion of Ross procedure indications to all patients requiring aortic valve replacement and prevented neo-aortic root dilatation. Failures were uncommon. Long-term follow-up data showed stable neo-aortic valve function. |
format | Online Article Text |
id | pubmed-9938391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-99383912023-02-19 Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation Guirgis, Lisa Hascoet, Sébastien Van Aerschot, Isabelle Radojevic, Jelena Ly, Mohamed Cohen, Sarah Belli, Emre JTCVS Tech Congenital: Aortic Valve BACKGROUND: Pulmonary autograft reinforcement to prevent dilatation and subsequent neo-aortic valve regurgitation has been reported; however, data on long-term function of the neo-aortic valve after this modified Ross procedure are lacking. Our objective here was to assess long-term outcomes of the modified Ross procedure with autograft reinforcement using the reimplantation technique. PATIENTS: The outcomes of 61 consecutive patients managed using the Dacron-conduit reinforced Ross procedure between 2009 and 2021 were reviewed. Most patients had a unicuspid or bicuspid aortic valve (n = 52; 85%), predominant aortic valve regurgitation (n = 42; 77%), and >30 mm dilatation of the ascending aorta (n = 33; 54%). A prior aortic valve procedure was noted in 47 patients (77%) patients, including 38 (62%) with surgical repair and 9 (15%) with balloon dilatation. The pulmonary autograft was reimplanted within a Dacron conduit with a median diameter of 25.6 mm (range, 20-30 mm) using the David valve-sparing aortic root replacement technique. RESULTS: All patients survived. The median age at surgery was 16.8 years (range, 6-38 years). Neo-aortic valve replacement was required in 3 patients (4.9%; 95% CI, 0.34%- 12.7%) because of infective endocarditis, left ventricular false aneurysm, and leaflet perforation, respectively; the repeat procedure was done early in 2 of these patients (2 of 61; 3%). Six patients required right ventricular outflow conduit replacement, 5 by surgery and 1 percutaneously. The median duration of follow-up was 90 months (range, 10-124 months). The 5- and 10-year rates of reintervention-free survival were 84.3% (95% CI, 74%-95%) and 81.6% (95% CI, 72%-93%), respectively, and 5-year survival without aortic reintervention was 94.5% (95% CI, 88%-100%), with little change at 10 years. No patients experienced deterioration of initial neo-aortic valve function (ie, regurgitation or stenosis). CONCLUSIONS: Autograft reinforcement using the reimplantation technique allowed expansion of Ross procedure indications to all patients requiring aortic valve replacement and prevented neo-aortic root dilatation. Failures were uncommon. Long-term follow-up data showed stable neo-aortic valve function. Elsevier 2022-12-20 /pmc/articles/PMC9938391/ /pubmed/36820346 http://dx.doi.org/10.1016/j.xjtc.2022.11.016 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Congenital: Aortic Valve Guirgis, Lisa Hascoet, Sébastien Van Aerschot, Isabelle Radojevic, Jelena Ly, Mohamed Cohen, Sarah Belli, Emre Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation |
title | Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation |
title_full | Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation |
title_fullStr | Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation |
title_full_unstemmed | Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation |
title_short | Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation |
title_sort | outcomes after the ross procedure with pulmonary autograft reinforcement by reimplantation |
topic | Congenital: Aortic Valve |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938391/ https://www.ncbi.nlm.nih.gov/pubmed/36820346 http://dx.doi.org/10.1016/j.xjtc.2022.11.016 |
work_keys_str_mv | AT guirgislisa outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation AT hascoetsebastien outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation AT vanaerschotisabelle outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation AT radojevicjelena outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation AT lymohamed outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation AT cohensarah outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation AT belliemre outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation |